Klow (no TB-500): Research Blend Profile

Klow (no TB-500) is not a single molecule. It is a research formulation that combines three of the more heavily referenced peptides in the tissue-repair class into one preparation, so a laboratory can study their pathways in parallel rather than reconstituting three separate vials. Structurally it is the four-peptide KLOW blend with the actin-binding component removed, leaving the copper-matrix, cytoprotective, and anti-inflammatory arms. This profile describes what the blend contains, the role the literature assigns to each constituent, and how the three mechanisms stay distinct. For the class the components belong to, see the tissue-repair peptides overview.

What is Klow (no TB-500)?#

Klow (no TB-500) is a co-lyophilized research blend of three peptides: GHK-Cu (a copper tripeptide), BPC-157 (a synthetic pentadecapeptide), and KPV (the C-terminal tripeptide of α-melanocyte-stimulating hormone). The name signals its relationship to the standard KLOW formulation, which adds a fourth peptide, TB-500, derived from thymosin β4; that actin-binding component is omitted here. Because the blend is a mixture rather than a single compound, it has no single molecular formula, molecular weight, or CAS number. Its identity is the sum of its constituents, each of which carries its own verified molecular record. Each component is sourced and characterized individually before the three are combined into one vial, which is why the reliable reference points here are the three separate compound profiles rather than one quoted mass.

What does each constituent contribute?#

The reason three peptides are grouped in one preparation is that their mechanisms do not overlap. GHK-Cu is the only copper carrier of the three; the free tripeptide binds copper(II) in a 1:1 ratio, and its studied activity is copper-dependent, which is why its literature centers on copper-dependent gene modulation and extracellular-matrix remodeling. BPC-157 is studied for cytoprotective and angiogenic signaling, with reported activity at the nitric-oxide system and vascular growth pathways across tendon, gut, and vascular models. KPV is the anti-inflammatory member, a short α-MSH-derived tripeptide generally reported to modulate inflammatory signaling such as the NF-κB pathway, in work that describes activity independent of the melanocortin receptors. Three peptides, three separate targets, one vial.

That separation is the whole point of studying the components as a blend. This composition is the four-peptide KLOW blend with its actin arm removed, so it pairs GHK-Cu's copper-matrix chemistry with BPC-157's cytoprotective signaling and adds KPV's anti-inflammatory activity on top. A laboratory reaching for the Klow (no TB-500) preparation is choosing to study three of the four KLOW pathways in parallel while leaving the thymosin β4 fragment out of the mixture.

What does the research literature study?#

There is no combined-formulation literature for this blend itself; the research that exists is the separate preclinical record for each constituent. GHK-Cu is examined for copper-dependent gene modulation and matrix remodeling, a mechanism rooted in its copper-carrier chemistry. BPC-157 has a large preclinical record centered on cytoprotection and angiogenic signaling. KPV is studied for anti-inflammatory activity, including work in intestinal-barrier and NF-κB models. All three bodies of work are preclinical, conducted in cell culture and animal models, and none of it speaks to effects in humans. A blend does not merge these records into a single validated result; it places three independently studied peptides in one preparation for parallel investigation.

Where Klow (no TB-500) sits in the tissue-repair class#

The tissue-repair class Nexara tracks is anchored by single compounds such as GHK-Cu, BPC-157, and TB-500, plus the multi-peptide blends that combine them. This blend sits one component short of the full four-peptide KLOW formulation: it keeps the copper-matrix arm (GHK-Cu), the cytoprotective arm (BPC-157), and the anti-inflammatory arm (KPV), and drops the actin arm (TB-500). It is best read as a convenience preparation over three separate research subjects rather than a compound with its own mechanism, which is why each constituent keeps its own profile (GHK-Cu, BPC-157, KPV). For how the class is grouped and where the mechanisms diverge, the tissue-repair peptides overview is the parent reference.

Handling and storage#

Klow (no TB-500) is supplied as a single lyophilized solid containing all three peptides and is dissolved prior to use. Because it is co-lyophilized, it is handled as one preparation rather than three: the reconstitution primer covers solvent selection and avoiding aggregation, while the cold-chain article covers how stability changes once the powder is in solution. As with the rest of the catalog, bacteriostatic water for reconstitution is a separate item.

Sources and further reading#

• GHK peptide as a natural modulator of multiple cellular pathways (PMC4508379): review of the copper-dependent gene-modulation and matrix-remodeling research relevant to the GHK-Cu constituent.
• Sikiric et al., Stable Gastric Pentadecapeptide BPC 157 — cytoprotection/organoprotection review (PMC7096228): foundational review of the BPC-157 preclinical record.
• KPV, the C-terminal α-MSH tripeptide, exerts anti-inflammatory activity (PMID 18831197): study of KPV in intestinal-barrier and NF-κB inflammatory-signaling models.